All The Ways COVID Can Affect Your Heart, According To Doctors

We won’t know the full impact that COVID-19 has on our health for a long time, but it’s clear that, for many people, symptoms are intense and even linger for months — if not years. One of the things COVID-19 can affect in major ways is your cardiovascular system. Research and doctors’ day-to-day work show that the coronavirus and long COVID can cause everything from small problems that clear up on their own to major heart issues. Advertisement And why the latter happens to some people is not totally known. “The exact mechanisms for how COVID affects the heart are unclear. Some of the possible theories involve increased inflammation of the heart and arteries. … Low oxygen levels may also play a role,” said Dr. Jim Liu, a cardiologist at Ohio State University’s Wexner Medical Center. While it’s a mystery why this occurs, it’s clear that it does happen. Below, doctors explain the impact a COVID-19 infection can have on your heart and how you can protect yourself: Most COVID infections won’t cause heart issues, but some groups are at higher risk. “Thankfully, the more severe complications are very uncommon in mild disease and in previously healthy people,” said Dr. Allison Zielinski, a cardiologist at Northwestern Medicine in Illinois. “But the risk of these complications goes up with severe disease, particularly if hospitalised or incubated,” she added. Those who do experience these side effects while hospitalised will be tested and monitored by their doctor, too. Advertisement Additionally, older people, people who are immunosuppressed or who have preexisting cardiovascular disease, or who have other medical conditions like high blood pressure, obesity and diabetes are also at heightened risk, according to Zielinski. For those who do experience heart issues, it could lead to one (or a few) cardiovascular problems. For those who do experience heart issues during or after a COVID-19 infection, the range of symptoms is vast. Here are the cardiovascular problems people experience. Inflammation “One of the main complications can be inflammation of the heart muscle itself, which is called myocarditis, or around the heart, which is called pericarditis,” said Zielinski. While this sounds scary, Liu said, myocarditis usually resolves without any long-term complications. “In the most severe cases, myocarditis can result in heart failure where the heart is unable to pump effectively,” Liu said. Irregular heartbeat In some cases, Liu said, irregular heartbeat — also known as arrhythmias — can occur in people with severe COVID-19 infections. Advertisement “Arrhythmias can also be associated with myocarditis, some of which can make the heart beat so fast that it can’t pump blood effectively and can be fatal if untreated,” he said. POTS “The biggest thing I tend to see as a consequence of having … long COVID … from a cardiovascular standpoint, is what we call POTS, or postural orthostatic tachycardia syndrome,” said Dr. Martha Gulati, the director of preventive cardiology at Cedars-Sinai in California. According to the Cleveland Clinic, POTS is a syndrome that can result in dizziness, increased heart rate and fatigue when you go from lying down to standing up. Gulati said POTS is more common in women, and while some folks do recover on their own, symptoms continue to linger for many people. And there are things that doctors can do to manage the disorder, but those management techniques don’t work for all people. Heart attack complications A study led by Gulati and other Cedars-Sinai researchers found that people who had COVID-19 at the time they had a heart attack had a higher risk of death. Advertisement “We saw that they had a higher hospital mortality, almost three times more likely to die in that hospitalisation than somebody who was just having a heart attack without COVID,” Gulati said. Additionally, people with a COVID-19 infection and a heart attack were more likely to end up on a ventilator and receive haemodialysis. As for why, Gulati said it’s a bit of a chicken or the egg question. “Did they have the heart attack and COVID was incidentally there … or was it that they had COVID and they got a heart attack? Unfortunately, in our database, we can’t tell which one. We just know that they had COVID [at the time of the heart attack].” Gulati noted that the respiratory effects of COVID-19 can put stress on the heart. “It’s certainly a possibility that just by having COVID, there was a greater chance of developing a [heart attack], but it is a little bit hard with this particular study when we’re looking at big data from across the entire country,” she said. Disparities were evident, too: Black, Asian, Hispanic and Pacific Islander patients saw worse outcomes and received lower levels of care, the study found. Advertisement “The increased mortality, increased complications, disparity in our approach of caring for patients, just highlighted a lot of the things that we knew exist within our cardiology community even pre-pandemic, but certainly the pandemic just [highlighted] the disparities in our care in a very profound way,” Gulati said. AzmanL via Getty Images In rare cases, a COVID-19 infection can cause cardiovascular issues. Beyond this, long COVID can present a host of additional heart issues. According to Zielinski, some of the same issues mentioned above can occur in someone who suffers from long COVID. “These effects can be separated into two categories. So, the first is cardiovascular disease, and so these are the labeled diseases like myocarditis, pericarditis that have objective abnormalities on cardiac testing,” Zielinski said. The second category is cardiovascular symptoms, she said. These symptoms “don’t have any clear objective abnormalities on testing but still affect patients, and for that reason may be dismissed by health care providers,” Zielinski said. Advertisement Common long COVID cardiovascular symptoms include heart palpitations, chest pain, shortness of breath, exercise intolerance and an exaggerated heart rate, she said. The same risk factors Zielinski mentioned above are relevant for long COVID too, she said, but the condition can also affect people seemingly at random. “Many of

Cardiovascular Drugs Market Insights 2023: Projected Global Growth by 2029

2023 Cardiovascular Drugs Market Report: Comprehensive Insights The “Cardiovascular Drugs Market Report 2023” provides an in-depth analysis of the competitive landscape in the industry. This report sheds light on company profiles, financial metrics, market demand, innovations, and the global footprint of major players. If you’re involved in the Cardiovascular Drugs market or looking to enter, this report is your comprehensive guide. The global Cardiovascular Drugs market was valued at USD 6014.9 million in 2022 and is anticipated to reach USD 6361.2 million by 2029, witnessing a CAGR of 0.8% during the forecast period 2023-2029. Brief Description About Cardiovascular Drugs Market:- Cardiovascular Drugs and Therapy is a bimonthly peer-reviewed medical journal covering pharmacotherapy as it relates to cardiology. It was established in 1987 and is published by Springer Science+Business Media on behalf of the International Society of Cardiovascular Pharmacotherapy, of which it is the official journal. The editors-in-chief are Willem J. Remme (Carol Davila University of Medicine and Pharmacy) and Robert S. Rosenson (Icahn School of Medicine at Mount Sinai).HighlightsThe global Cardiovascular Drugs market was valued at USD 6014.9 million in 2022 and is anticipated to reach USD 6361.2 million by 2029, witnessing a CAGR of 0.8% during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.Geographically, North America captured lions share of global cardiovascular drugs market in 2016. However increasing adoption of generics in the U.S. is key concern area among key players. Asia Pacific market is projected to gain market share during the forecast period and is likely to be key revenue generator in the coming years. Initiatives by local governments to attain self-sufficiency in manufacturing pharmaceuticals and incentives for generic production in countries such as Brazil, South Africa, Saudi Arabia, etc. is likely to boost market growth in Latin America and Middle East and Africa.Report ScopeThis report aims to provide a comprehensive presentation of the global market for Cardiovascular Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cardiovascular Drugs.The Cardiovascular Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue (USD millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Cardiovascular Drugs market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.Sandeep Get a Sample Copy of theCardiovascular DrugsReport 2023 Highlights of the 2023 Cardiovascular Drugs Market Report: Detailed Analysis: From company financials to product launches, get a holistic view of factors influencing the market. Regional Outlook: Understand market growth across APAC, Europe, North America, South America, and Middle East and Africa. Market Predictions: Accurate market size forecasts and trend predictions up to 2029. Competitive Analysis: Discover the strategies, market contributions, and recent developments of leading companies. This includes: Amgen AstraZeneca Bayer Bristol Myers Squibb and Pfizer Daiichi Sankyo Johnson and Johnson Merck and Co. Novartis Pfizer Portola Sanofi In Chapter 5 and Chapter 7.3, based on types, the Cardiovascular Drugs market from 2018 to 2029 is primarily split into: Renin-Angiotensin System Blockers Beta Blockers Diuretics Anti-Clotting Agents Antihyperlipidemic In Chapter 6 and Chapter 7.4, based on applications, the Cardiovascular Drugs market from 2018 to 2029 covers: Hypertension Hyperlipidemia Get a Sample PDF of report –https://www.industryresearch.biz/enquiry/request-sample/23452040 Key Insights Include: Expected CAGR during the forecast period. Analysis of factors driving Cardiovascular Drugs market growth. In-depth vendor analysis. Impact of External Factors: Understanding the influence of the COVID-19 pandemic and the Russia-Ukraine war on the Cardiovascular Drugs market. Why Choose This Report? Deep market segmentation analysis. Insights into market growth and driving factors. Detailed vendor landscape and competitive analysis. Current trends and challenges in the Cardiovascular Drugs market. For any queries, click here. [Detailed TOC of Global Cardiovascular Drugs Market Insights and Forecast to 2029] 1 Cardiovascular Drugs Market Overview 1.1 Product Overview and Scope of Cardiovascular Drugs Market 1.2 Market Segment by Type 1.2.1 Global Market Sales Volume and CAGR (%) Comparison by Type (2018-2029) 1.3 Global Market Segment by Application 1.3.1 Market Consumption (Sales Volume) Comparison by Application (2018-2029) 1.4 Global Market, Region Wise (2018-2029) 1.4.1 Global Market Size (Revenue) and CAGR (%) Comparison by Region (2018-2029) 1.4.2 United States Market Status and Prospect (2018-2029) 1.4.3 Europe Market Status and Prospect (2018-2029) 1.4.4 China Market Status and Prospect (2018-2029) 1.4.5 Japan Market Status and Prospect (2018-2029) 1.4.6 India Market Status and Prospect (2018-2029) 1.4.7 Southeast Asia Market Status and Prospect (2018-2029) 1.4.8 Latin America Market Status and Prospect (2018-2029) 1.4.9 Middle East and Africa Market Status and Prospect (2018-2029) 1.5 Global Market Size of (2018-2029) 1.5.1 Global Market Revenue Status and Outlook (2018-2029) 1.5.2 Global Market Sales Volume Status and Outlook (2018-2029) 1.6 Global Macroeconomic Analysis 1.7 The impact of the Russia-Ukraine war on the Cardiovascular Drugs Market 2 Industry Outlook 2.1 Cardiovascular Drugs Industry Technology Status and Trends 2.2 Industry Entry Barriers 2.2.1 Analysis of Financial Barriers 2.2.2 Analysis of Technical Barriers 2.2.3 Analysis of Talent Barriers 2.2.4 Analysis of Brand Barrier 2.3 Cardiovascular Drugs Market Drivers Analysis 2.4 Market Challenges Analysis 2.5 Emerging Market Trends 2.6 Consumer Preference Analysis 2.7 Industry Development Trends under COVID-19 Outbreak 2.7.1 Global COVID-19 Status Overview 2.7.2 Influence of COVID-19 Outbreak on Industry Development 3 Global Cardiovascular Drugs Market Landscape by Player 3.1 Global Cardiovascular Drugs Sales Volume and Share by Player (2018-2023) 3.2 Global Revenue and Market Share by Player (2018-2023) 3.3 Global Average Price by Player (2018-2023) 3.4 Global Gross Margin by Player (2018-2023) 3.5 Market Competitive Situation and Trends 3.5.1 Market Concentration Rate 3.5.2 Market Share of Top 3 and Top 6 Players 3.5.3 Mergers and Acquisitions, Expansion 4 Global Cardiovascular Drugs Sales Volume

Non-alcoholic fatty liver disease: How resistant starch can be helpful

Share on PinterestSupplements can sometimes help people with non-alcoholic fatty liver disease. FootageStockEasy/Getty Images Researchers are reporting that resistant starch may help lower inflammation in people with non-alcoholic fatty liver disease. Legumes and whole grains are among the natural sources of resistant starch. Experts say a healthy lifestyle and healthy weight can help prevent the onset of fatty liver disease. New research indicates that resistant starch may positively affect metabolism. According to a study published today in the journal Cell Metabolism, this type of starch could also help reduce liver injury and inflammation, lowering the risk of developing non-alcoholic fatty liver disease (NAFLD). In their study, researchers recruited 200 people with NAFLD. They provided the participants with a balanced diet designed by a nutritionist. Half of the participants received a resistant starch powder derived from maize. The other half received a calorie-matched, non-resistant corn starch. The scientists instructed both groups to drink 40 grams of the starch mixed with 300 milliliters (1 ¼ cups) of water before meals twice a day for four months. After four months, researchers reported that the group that received the resistant starch treatment had almost a 40% lower liver triglyceride level compared to people in the control group. They also had reduced liver enzymes and inflammatory factors associated with NAFLD. The improvements remained when the scientists statistically adjusted for weight loss. In the second stage of this study, the researchers analyzed fecal samples from the participants. They found the resistant starch group had a different microbiota composition. The treatment group had a lower level of Bacteroides stercoris, a type of bacteria that can affect fat metabolism in the liver. The researchers transplanted fecal microbiota from the resistant starch treatment participants to mice with a high fat, high cholesterol diet. The researchers reported that there was a significant reduction in liver weight and triglyceride levels and improved liver tissue grading in the mice compared to those that received microbiota from the control group. “This study provides a very interesting mechanism on the potential role of the gut microbiome and fatty liver disease,” Dr. Hardeep Singh, a gastroenterologist with Providence St. Joseph Hospital in Orange in California who was not involved in the study, told Medical News Today. “It does provide some promising results. However, the data is very preliminary and, at this point, not something I would recommend to patients as a treatment option for fatty liver disease. Further study is required,” he added. A buildup of fat in the liver can cause NAFLD. This can lead to severe liver disease and contribute to other medical conditions, such as type 2 diabetes and cardiovascular disease. These conditions also make you more likely to develop NAFLD. “Treatment options for fatty liver disease are limited at this time,” Singh said. “Unfortunately, currently, there are no medications that have been proven to be effective for this condition. Weight loss via diet and lifestyle modification is the mainstay of therapy.” “A study showed that weight loss for morbidly obese patients via bariatric surgery can reduce fatty liver disease and scarring in the liver,” Singh added. “Multiple studies, such as this one and this one, have confirmed that 2 to 3 cups of coffee per day is effective at reducing fat and scarring in the liver in patients with fatty liver disease. We do advocate for coffee intake in patients who can tolerate 2 to 3 cups of coffee per day. The coffee has to be regular black coffee and not decaf. A few studies have documented improvement in fatty liver disease using vitamin E 800 units per day. This can be considered in select patients.” NAFLD is an accumulation of fats in the liver. Sometimes, these cause injury, inflammation, or fibrosis. These effects can sometimes be avoided by maintaining a healthy lifestyle, according to the Ohio State University, Wexner Medical Center. Following the Mediterranean diet could help, as well as monitoring your intake of simple sugars. “In some specific situations, fatty liver disease may be prevented,” Singh said. “What I mean by this is if you are obese or overweight, that will lead to insulin resistance and eventual metabolic syndrome. That is a precursor to fatty liver disease. In some patients, this can be modified and altered with lifestyle modification. Therefore, if those patients become more active and lose weight, their insulin resistance can be reduced, and they may not develop fatty liver disease.” “However, in another subset of patients with more aggressive genetics, I don’t believe fatty liver disease can be prevented,” he added. “For example, just as we have skinny patients who develop diabetes, there are a subset of patients with fatty liver disease who have a normal body mass index and no risk factors for metabolic syndrome. In those patients, the condition cannot be prevented as it appears they have a genetic predisposition.” “Resistant starch is a type of carbohydrate that acts more as a fiber than a starch,” according to Caroline Thomason, RD, CDCES, a dietitian based in Washington, D.C., who was not involved in the study. “It is digested slowly and has positive health applications for diabetes, heart disease, and digestive health.” “Anywhere between 20 grams to 50 grams of resistant starch has been studied in the research with the few side effects,” Thomason told Medical News Today. “Too much resistant starch may cause some gas and bloating in sensitive folks.” “Foods with resistant starch are often cooked – then – cooled carbohydrates,” she added. “This means if you cook white rice, let it cool in the fridge, and reheat it later as part of a meal, you will benefit from resistant starch. You may find that your blood sugar doesn’t rise quickly, and you feel fall longer, in addition to any other potential health benefits of resistant starch.” There isn’t a recommended daily allowance for resistant starches. Experts note that it is healthy to get fiber from a wide range of sources so that you have soluble, insoluble, and resistant starches every day.

[Trends ] Cardiovascular Information System Market Growth Drivers along with Top Brands Analysis [123+ Pages Report]

Cardiovascular Information System Market with analysis of such parameters i.e. industry growth drivers, supply and demand, risks, market attractiveness, annual growth comparison, BPS analysis, SWOT analysis and Porter’s Five Forces model. Cardiovascular Information System Market report gives inside and out audit of the Expansion Drivers, Potential Challenges, Distinctive Trends, and Opportunities for Market Players. Our Research experts have carried out detailed checks of the critical environment and have predicted the methodological structure used by market participants. The primary goal of the Cardiovascular Information System business report is to supply key insights on competition positioning, current scope, market potential, growth rates, and alternative relevant statistics. List of Top Key Players in Cardiovascular Information System Market Report Are: The survey describes the qualities of the entire company based on industry-wide analysis. Lumedx Merge Healthcare Cerner Corporation GE Healthcare Fujifilm Medical Systems McKesson Corporation Digisonics Philips Healthcare Agfa Healthcare Siemens Healthcare Get a Sample PDF of report @ https://www.360marketupdates.com/enquiry/request-sample/20949543 Cardiovascular Information System Market Report Contains 2023: – Complete overview of the global Cardiovascular Information System Market Top Country data and analysis for United States, Canada, Mexico, Germany, France, United Kingdom, Russia, Italy, China, Japan, Korea, India, Southeast Asia, Australia, Brazil and Saudi Arabia, etc. It also throws light on the progress of key regional Cardiovascular Information System Markets such as North America, Europe, Asia-Pacific, South America and Middle East and Africa Description and analysis of Cardiovascular Information System market potential by type, Deep Dive, disruption, application capacity, end use industry impact evaluation of most important drivers and restraints, and dynamics of the global Cardiovascular Information System Market and current trends in the enterprise Cardiovascular Information System Market Summary: Cardiovascular Information System Marketsize, segment (mainly coveringMajorType (, Web-based, Onsite, ,),End Users (, Catheterization, ECG, Holter, ICD, Electrocardiography,), and regions), recent status, development trendsa and competitor landscape. Furthermore, the 123 pages report provides detailed cost analysis, supply chain. Technological innovation and advancement will further optimize the performance of the product, making it more widely used in downstream end users. Also, Consumer behaviour analysis and market dynamics (drivers, restraints, opportunities) provides crucial information for knowing the Cardiovascular Information System market. Ask For A Sample Copy of the Report Global Cardiovascular Information System Market: Market Segmentation Analysis The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments. Based on Product Type, this report shows the creation, income, cost, piece of the pie, and development pace of each kind, principally split into: Web-based Onsite On the Basis of the End-User/Applications, this report focuses on the status and outlook for major applications production, revenue, price, market share, and growth rate: Catheterization ECG Holter ICD Electrocardiography Enquire before purchasing this report – https://www.360marketupdates.com/enquiry/pre-order-enquiry/20949543 Key Benefits of This Market Research: Industry drivers, restraints, and opportunities covered in the study Neutral perspective on the market performance Recent industry trends and developments Competitive landscape and strategies of key players Potential and niche segments and regions exhibiting promising growth covered Historical, current, and projected market size, in terms of value In-depth analysis of the Cardiovascular Information System Market Overview of the regional outlook of the Cardiovascular Information System Market Valuable Points from Cardiovascular Information System Market Research Report 2022-2028: Significant changes in Market dynamics. Reporting and assessment of recent industry developments. A complete background analysis, which includes a valuation of the parental Cardiovascular Information System Market. Current, Historical, and projected size of the Cardiovascular Information System Market from the viewpoint of both value and volume. Cardiovascular Information System Market segmentation according to Top Regions. Cardiovascular Information System Market shares and strategies of key Manufacturers. Emerging Specific segments and regional for Cardiovascular Information System Market. An objective valuation of the trajectory of the Market. Recommendations to Top Companies for reinforcement of their foothold in the market. Cardiovascular Information System Market Report Gives Answers to Following Key Questions: What will the growth rate of the Cardiovascular Information System market be? What is the analysis of the sales volume, sales and prices of the leading manufacturers in the Cardiovascular Information System market? What are the key drivers of the Global Cardiovascular Information System Market? Who are the major players in the Cardiovascular Information System market? Who are the key market players in the Cardiovascular Information System Market? Which Market opportunities, risks and business strategies adopted by them? What are the Cardiovascular Information System market opportunities and threats facing suppliers in the global Cardiovascular Information System Industry? What is the regional sales, revenue and price analysis of the Cardiovascular Information System industry? Who are the distributors, traders and resellers in the Cardiovascular Information System market? Which are the major regions for dissimilar trades that are expected to eyewitness astonishing growth for the Cardiovascular Information System Market? What are the regional growth trends and the leading revenue-generating regions for the Cardiovascular Information System Market? Request for a Sample PDF of Report: https://www.360marketupdates.com/enquiry/request-sample/20949543 Key Reasons to Buy this Report: Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analysed to tell you why your market is set to change This enables you to anticipate market changes to remain ahead of your competitors You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly Provision of market value (USD Billion) data for each segment and sub-segment Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are

Cardiovascular Device Company Exceeds Patient Enrollment Goals Six Months Ahead of Schedule

Learn how a medical device company scaled its post-market trial for cardiovascular grafts and patches to meet new EU MDR requirements during the global pandemic. With a flexible approach, IQVIA MedTech used its cardiovascular post-market clinical experience to exceed patient enrollment goals six months ahead of schedule. Discover how IQVIA MedTech: Activated 31 sites across seven countries Helped the sponsor maintain EU MDR compliance on five legacy medical devices Leveraged its therapeutic area expertise to enroll and retain over 1,600 patients for a post-market cardiovascular trial that required long-term follow-up

NHS expands local blood pressure checks to help prevent cardiovascular illnesses

For free real time breaking news alerts sent straight to your inbox sign up to our breaking news emails Sign up to our free breaking news emails The NHS is expanding blood pressure checks available in local communities as part of a major drive to prevent strokes and heart attacks. NHS figures show high street pharmacies delivered a total of 149,865 blood pressure checks to the over 40s in May 2023, more than double the 58,345 delivered the year before. New funding as part of the primary care access recovery plan will see a further 2.5 million blood pressure checks in community pharmacies, which are estimated to prevent more than 1,350 cardiovascular events each year. As part of the scheme, mobile sites have visited places such as barber shops, supermarkets, mosques and dominoes clubs so that local teams can find potential health problems for patients at locations that are most convenient. At a time when the NHS is busier than ever, making more of these free checks available in local communities has the potential to help millions more people improve their heart health, and prevent more heart attacks and strokes John Maingay, British Heart Foundation David Webb, chief pharmaceutical officer for England, said: “The enormous expansion in the number of blood pressure checks delivered over the last year is thanks to the hard work of community pharmacies which have more than doubled the number of blood pressure checks delivered, and the innovation of local teams, going into the heart of communities with mobile sites that can visit places like barber shops and dominoes clubs. “With the number of people living with major illnesses including heart disease and other cardiovascular conditions set to grow substantially over the coming years, it has never been more important to put in place preventative measures like easy to access blood pressure checks that can pick up the early signs and risks, with figures showing teams are on track to prevent more than 1,300 heart attacks and strokes this year alone.” The Health Foundation estimates that 9.1 million people will be living with a major illness by 2040, 2.5 million more than in 2019. John Maingay, director of policy and influencing at the British Heart Foundation, urged people to take up the local checks. He said: “Having high blood pressure can significantly increase your risk of having a heart attack and stroke, but it can be difficult to know you have it unless you check because it doesn’t usually have any obvious symptoms. “At a time when the NHS is busier than ever, making more of these free checks available in local communities has the potential to help millions more people improve their heart health, and prevent more heart attacks and strokes. “We urge everyone to take up a free blood pressure check in your neighbourhood – it’s quick, easy, and could help save your life.”

Price tag on cardiovascular disease in Europe higher than entire EU budget: Study

Credit: Unsplash/CC0 Public Domain Cardiovascular disease (CVD) cost the EU an estimated €282 billion in 2021, according to late breaking research presented at ESC Congress 2023. Health and long-term care accounted for €155 billion (55%) of these costs, equaling 11% of EU health expenditure. The findings are published in the European Heart Journal, and the analysis was a collaborative effort by the European Society of Cardiology (ESC) and the University of Oxford, UK. Study author Dr. Ramon Luengo-Fernandez of the University of Oxford said, “CVD had a significant impact on the EU27 economy, costing a total of €282 billion in 2021. That’s equivalent to 2% of Europe’s GDP and is significantly more than the entire EU budget itself, used to fund research, agriculture, infrastructure and energy across the Union.” This was the most comprehensive and up-to-date analysis of the economic costs of CVD to society in the EU since 2006. It is the first study to use Europe-wide patient registries and surveys rather than relying on assumptions and, unlike previous reports, includes the costs of long-term social care. The current analysis provides estimates of the societal economic costs of CVD for the 27 members states of the EU in 2021, including 1) health and social care; 2) informal care; and 3) productivity losses. The breakdown includes: €130 billion for health care (46%) €25 billion for social care (9%) €79 billion for informal care (28%) €15 billion in productivity losses due to illness/disability (5%) €32 billion in productivity losses due to premature death (12%). The total cost equated to €630 per EU citizen, ranging from €381 in Cyprus to €903 in Germany. CVD cost health and social care systems approximately €155 billion in 2021, accounting for 11% of total health care expenditure. There was wide variation between countries in the proportion of health care budgets spent on CVD, from 6% in Denmark to 19% in Hungary. Health care included primary care, emergency care, hospital care, outpatient care and medications, while social care included long-term institutionalized care, and care at home. The main contributor was hospital care, which cost €79 billion, representing 51% of CVD-related care costs. CVD medications accounted for €31 billion (20%) of care costs, followed by residential nursing care homes at €15 billion (9%). Informal care costs included the work or leisure time, valued in monetary terms, that relatives and friends gave up to provide unpaid care. Relatives and friends provided 7.5 billion hours of unpaid care for patients with CVD, amounting to €79 billion across the EU. Productivity losses included lost earnings due to illness/disability (early retirement/absenteeism) or premature death. In 2021, 256 million working-days were lost in the EU because of CVD illness/disability, at a cost of €15 billion. That same year, 1.7 million people died due to CVD across the EU, representing 1.3 million working-years lost, and generating productivity losses of €32 billion. ESC Board member and study author Professor Victor Aboyans of Limoges University, France said, “This study underscores the urgent need to act collectively on the European scale to better combat the cardiovascular risk of European citizens, in particular through regulations for better cardiovascular prevention and investment in research. By choosing not to invest in cardiovascular disease we are simply deferring the cost. These data force us to ask the question: do we invest in cardiovascular health today or be forced to pay more at a later stage?” Professor Panos Vardas, chief strategy officer of the European Heart Agency, the ESC’s office in Brussels, said, “Today’s presentation provides a clear understanding of the overall economic burden of cardiovascular disease across different EU countries, offering the opportunity to draw valuable conclusions that are useful for those responsible for designing health care plans.” “It is evident that there is significant fragmentation among EU countries in terms of cardiovascular disease health care expenditures. This necessitates a re-evaluation by the EU as a whole, and the 27 EU countries individually, to better address the outstanding needs and invest more effectively in supporting those suffering from cardiovascular disease.” More information: Ramon Luengo-Fernandez et al, Economic burden of cardiovascular diseases in the European Union: a population-based cost study, European Heart Journal (2023). DOI: 10.1093/eurheartj/ehad583 Provided by European Society of Cardiology Citation: Price tag on cardiovascular disease in Europe higher than entire EU budget: Study (2023, August 28) retrieved 28 August 2023 from https://medicalxpress.com/news/2023-08-price-tag-cardiovascular-disease-europe.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

FDA clears new smart scale capable of detecting AFib, other cardiovascular issues

Withings, the healthcare technology company known for its remote monitoring devices, announced that the U.S. Food and Drug Administration (FDA) has cleared its newest smart scale, the Body Scan Connected Health Station. Body Scan includes a high-strength glass platform with four weight sensors and 14 ITO electrodes and a retractable handle that includes four additional stainless steel electrodes for performing 6-lead electrocardiograms. The device evaluates a user’s body composition, heart rate and vascular age, and it was designed to identify any signs of atrial fibrillation (AFib). Body Scan also gives users access to personalized recommendations and can connect directly with a healthcare specialists when needed. Once Body Scan’s sensors perform an ECG, the devices use advanced artificial intelligence to identify and track heart patterns known to be found in AFib patients. The results are displayed both on the device’s LCD screen and the user’s smartphone application. These results are saved, allowing them to be compared as time goes on, and they can be shared directly with healthcare providers.

Intravascular imaging-guided PCI improves patient outcomes, new meta-analysis confirms

The final analysis included data from the ILUMIEN IV trial, OCTOBER trial and several previously completed studies comparing intravascular imaging-guided PCI and angiography-guided PCI. Adding up all of the included trials, researchers were left to compare 7,038 patients treated with intravascular imaging-guided PCI, including 3,120 who underwent IVUS-guided PCI, 2,826 who underwent OCT-guided PCI and another 1,029 who were randomized to undergo IVUS- or OCT-guided PCI. These patients were compared with 5,390 treated with angiography-guided PCI, and each participant was followed for a period of 6 months to five years. The primary endpoint of the meta-analysis was target lesion failure, which the authors defined as a composite of cardiac death, target vessel myocardial infarction (MI) or target lesion revascularization. Overall, intravascular imaging-guided PCI helped reduce that composite endpoint by 31%. It also was linked to significant reductions in cardiac death, target vessel MI, target lesion revascularization and stent thrombosis. “The results of this network meta-analysis emphasize the importance of physicians using intravascular imaging with either OCT or IVUS to optimize stent outcomes and improve the long-term prognosis of their patients,” Gregg Stone, MD, a cardiologist and professor of cardiology with Icahn School of Medicine at Mount Sinai in New York, said in a statement. Additional ESC Congress 2023 coverage is available here, here and here.